Biotech Values

[poorgradstudent]

INCY:

Was the implication that Baricitinib will be safer than Jakafi in combination therapy?

Actually, I need to amend the notes as this is a mistake. It was a comparison of baricitinib to tofacitinib, not ruxolitinib. My mistake / apologies.

Advantages they noted in the CC:

- once a day versus twice a day as an advantage for baricitinib over tofacitinib.
- reduced number of drug interactions because it is not cleared in the liver as tofacitinib is.

Potential advantage, which they think might be borne out in the clinical studies:

-better safety profile in terms of Infections because it is not a JAK3 inhibitor


Again, the comparison was baricitinib versus tofacitinib, Pfizer's drug.